DE69819911D1 - 88kda tumorgener wachstumsfaktor und antagonisten - Google Patents

88kda tumorgener wachstumsfaktor und antagonisten

Info

Publication number
DE69819911D1
DE69819911D1 DE69819911T DE69819911T DE69819911D1 DE 69819911 D1 DE69819911 D1 DE 69819911D1 DE 69819911 T DE69819911 T DE 69819911T DE 69819911 T DE69819911 T DE 69819911T DE 69819911 D1 DE69819911 D1 DE 69819911D1
Authority
DE
Germany
Prior art keywords
antagonists
88kda
tumorrow
growth factor
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69819911T
Other languages
English (en)
Other versions
DE69819911T2 (de
Inventor
Ginette Serrero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69819911D1 publication Critical patent/DE69819911D1/de
Application granted granted Critical
Publication of DE69819911T2 publication Critical patent/DE69819911T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69819911T 1997-05-23 1998-05-22 88kda tumorgener wachstumsfaktor und antagonisten Expired - Lifetime DE69819911T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86307997A 1997-05-23 1997-05-23
US863079 1997-05-23
US08/991,862 US6309826B1 (en) 1997-05-23 1997-12-16 88kDa tumorigenic growth factor and antagonists
US991862 1997-12-16
PCT/US1998/010555 WO1998052607A1 (en) 1997-05-23 1998-05-22 88kda tumorigenic growth factor and antagonists

Publications (2)

Publication Number Publication Date
DE69819911D1 true DE69819911D1 (de) 2003-12-24
DE69819911T2 DE69819911T2 (de) 2004-09-02

Family

ID=27127743

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69819911T Expired - Lifetime DE69819911T2 (de) 1997-05-23 1998-05-22 88kda tumorgener wachstumsfaktor und antagonisten

Country Status (10)

Country Link
US (3) US6309826B1 (de)
EP (2) EP1011723B1 (de)
AT (1) ATE254476T1 (de)
AU (1) AU7797898A (de)
CA (1) CA2290602C (de)
DE (1) DE69819911T2 (de)
DK (1) DK1011723T3 (de)
ES (1) ES2213906T3 (de)
PT (1) PT1011723E (de)
WO (1) WO1998052607A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720159B1 (en) * 1997-12-16 2004-04-13 A&G Pharmaceutical, Inc. 88KDA tumorigenic growth factor and antagonists
US8512960B2 (en) * 1997-05-23 2013-08-20 A&G Pharmaceutical, Inc. 88kDa tumorigenic growth factor and antagonists
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6309826B1 (en) 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US6872703B2 (en) * 2000-06-07 2005-03-29 Ajinomoto Co., Inc. Insulin receptor-related receptor binding protein
AU2007229401B2 (en) * 2001-06-15 2011-10-06 A & G Pharmaceuticals, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic efffects of antiestrogen therapy
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
WO2004078782A1 (en) * 2003-02-26 2004-09-16 A & G Pharmaceuticals, Inc. Methods for increasing the proliferation of b cells
WO2005000240A2 (en) * 2003-06-23 2005-01-06 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
EP1849480A3 (de) * 2003-06-23 2013-06-26 A & G Pharmaceutical, Inc. Zusammensetzungen und Verfahren zur Wiederherstellung der Empfindlichkeit von Tumorzellen gegen die Antitumorbehandlung und zur Induzierung von Apoptose
US20070065887A1 (en) * 2003-07-21 2007-03-22 Kinch Michael S Diagnosis of pre-cancerous conditions using pcdgf agents
WO2005011590A2 (en) 2003-08-01 2005-02-10 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with her2 antagonists
US20050244839A1 (en) * 2004-04-29 2005-11-03 Cheung Siu T Granulin-epithelin precursor (GEP) overexpression as a target for diagnosis, prognosis and treatment of hepatocellular carcinoma (HCC)
CA2584862A1 (en) * 2004-10-13 2006-04-27 A&G Pharmaceutical, Inc. Autocrine growth factor receptors and methods
DE102005033237B4 (de) * 2005-07-15 2007-09-20 Siemens Ag Verfahren zur Bestimmung und Korrektur von Fehlorientierungen und Offsets der Sensoren einer Inertial Measurement Unit in einem Landfahrzeug
JP5123936B2 (ja) 2006-05-30 2013-01-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 認知症の検出および治療
DK2037948T3 (en) * 2006-05-30 2016-08-01 Mayo Foundation Detection and treatment of dementia
US8057579B2 (en) * 2008-11-10 2011-11-15 General Electric Company Method, apparatus, and system for acid gas removal
KR101229821B1 (ko) 2010-11-09 2013-02-05 가톨릭대학교 산학협력단 그래뉼린-에피테린 전구체 유전자의 발현을 억제하는 안티센스 및 이를 함유하는 약제학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US20030215445A1 (en) * 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6720159B1 (en) * 1997-12-16 2004-04-13 A&G Pharmaceutical, Inc. 88KDA tumorigenic growth factor and antagonists
US6309826B1 (en) * 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
DE60106281T2 (de) 2000-08-11 2005-02-24 Wyeth Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods

Also Published As

Publication number Publication date
ES2213906T3 (es) 2004-09-01
WO1998052607A1 (en) 1998-11-26
CA2290602A1 (en) 1998-11-26
EP1356824A3 (de) 2004-02-04
EP1011723B1 (de) 2003-11-19
DK1011723T3 (da) 2004-03-22
EP1011723A1 (de) 2000-06-28
DE69819911T2 (de) 2004-09-02
EP1356824A2 (de) 2003-10-29
PT1011723E (pt) 2004-04-30
EP1011723A4 (de) 2001-12-05
US20040131618A1 (en) 2004-07-08
ATE254476T1 (de) 2003-12-15
US20020061859A1 (en) 2002-05-23
US7592318B2 (en) 2009-09-22
US6670183B2 (en) 2003-12-30
AU7797898A (en) 1998-12-11
US6309826B1 (en) 2001-10-30
CA2290602C (en) 2015-10-06

Similar Documents

Publication Publication Date Title
DE69819911D1 (de) 88kda tumorgener wachstumsfaktor und antagonisten
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
FR12C0004I1 (de)
DE69327231D1 (de) Kalzifizierungsverhütende behandlung für aldehydgegerbte biologische gewebe
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
ATE446365T1 (de) Menschliches fgf-21 gen und genexpressionsprodukte
ATE237234T1 (de) Haustierfutter geeignet zur zahnpflege der haustiere
DE69830591D1 (de) HEILUNG VON BRUCHVERLETZUNGEN UNTER VERWENDUNG VON PTHrP ANALOGEN
DE59008148D1 (de) Anordnung zur Gewebestimulation.
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
BR9606298A (pt) Peixe transgênico no tratamento de diabetes
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
GB2370750B (en) Method for treating fertilized chicken eggs and method for hatching the fertilized eggs
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
ZA989313B (en) Novel compounds for treating diseases associated with the biological effect of endothelin.
ATE364180T1 (de) Screeningverfahren mit bnpi und dnpi
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
ES2093840T3 (es) Compuestos del germanio y su utilizacion como aceite biocompatible.
ATE94759T1 (de) Verwendung von dextransulfat, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen protatakarzinoms.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition